| Document |
Document Title |
|
WO/2007/138998A1 |
Disclosed is a pharmaceutical composition which is effective for the treatment or prevention of a disease associated with uric acid, such as hyperuricemia, tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary cal...
|
|
WO/2007/139002A1 |
It is intended to provide a method for producing an excellent compound effective in the treatment, prevention or the like of pathological conditions associated with uric acid such as hyperuricemia, tophus, acute gouty arthritis, chronic ...
|
|
WO/2007/135293A2 |
The invention especially relates to 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation thereof, compositions containing the same, and the use thereof as medicaments, especially anticancer drugs. Formula (I).
|
|
WO/2007/132841A1 |
Disclosed is a serotonin 5-HT2C receptor activator comprising a compound represented by the formula below or a salt or prodrug thereof: (I) wherein the ring A represents a 5- or 6-membered aromatic heterocyclic ring which may have a subs...
|
|
WO/2007/126020A1 |
[PROBLEMS] To provide a novel compound having an activity of blocking an NMDA receptor channel, and also provide a pharmaceutical agent comprising the compound. [MEANS FOR SOLVING PROBLEMS] A pharmaceutical agent for the treatment or pre...
|
|
WO/2007/121523A1 |
Oxcarbazepine having a D[v,0.5] value of between about 15 microns to about 30 microns and a D[v,0.9] value of less than or equal to 90 microns.
|
|
WO/2007/123516A1 |
The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein t...
|
|
WO/2007/118651A1 |
A process for preparing compounds of formula (I) or a solvate or hydrate thereof, where R, R1, R2, R3 and R5 have the meanings as indicated in the specification. Such compounds are useful in the treatment of a number of conditions associ...
|
|
WO/2007/120517A2 |
The present invention provides processes, methods and intermediates for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, salts, hydrates and crystal forms thereof which are useful as serotonin (5-HT) receptor ago...
|
|
WO/2007/120589A2 |
An efficient syntheses for the preparation of (3R,6S)-3-amino-6-(2,3- difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one. The process uses a crystallization driven asymmetric transformation to set the amine stereocenter followed by a c...
|
|
WO/2007/115943A2 |
Process for the preparation of an N-alkyl lactam with improved colour quality, where 0.01 to 10% by weight of a C1-10-alcohol or a compound which releases 0.01 to 10% by weight of a C1-10-alcohol is added to the N-alkyl lactam. Mixture c...
|
|
WO/2007/117166A1 |
A process for preparing a compound of the formula IA or IB, wherein R is a!kyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group; the term alkyl means carbon chain, str...
|
|
WO/2007/117180A1 |
The invention relates to novel azaheterocycles of interest as potential physiologically active substances (agonists, antagonists, receptor modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agent etc.), to combin...
|
|
WO/2007/110335A1 |
The invention relates to malonamide derivatives of Formula (I) wherein A1 is -CHR- or -C(O)-; A2 is -C(O)- and R2/R3 are independently from each other hydrogen, lower alkyl, halogen, hydroxy or lower alkoxy; or A2 is -O-C(O)- and R2/R3 a...
|
|
WO/2007/105482A1 |
A process for the production of amides or lactams by conducting the rearrangement of an oxime in the presence of a cyclic compound having a structure represented by the general formula (1) as a ring constituent and a fluorinated alcohol ...
|
|
WO/2007/104933A1 |
The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutical...
|
|
WO/2007/101347A1 |
Disclosed herein are compounds as resented by Formula (I): wherein R1,R2, R3, R4, n, W, A, and Q are as defined herein. The compounds of formula (I) are useful as antagonists of the IAPs via binding to BIR domain. The compounds are usefu...
|
|
WO/2007/102171A2 |
Novel water soluble amino acid salts of 1 H- 1-benzazepine- 1 -acetic acid, process of preparation of such novel salts and methods of using them are provided. Also provided are pharmaceutical compositions comprising such novel salts and ...
|
|
WO/2007/088878A1 |
Disclosed is a commercial method which is practically suitable for producing a 2-iminocarboxylic acid derivative and a benzazepinone by a short process under mild conditions. Specifically disclosed is a method for producing a benzazepino...
|
|
WO/2007/079957A1 |
The invention relates to the substituted propiolic acid amides of general formula (I), to methods for producing them, to drugs containing said compounds and to the use thereof for producing drugs.
|
|
WO/2007/080131A2 |
Compounds of formula (I) wherein the substituents are as defined in claim (1), and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredie...
|
|
WO/2007/074553A1 |
According to the invention, a catalyst for a strecker reaction comprising a quaternary ammonium salt and a method for stereoselectively producing an α-aminonitrile derivative using the same are provided. By using the α-aminonitrile der...
|
|
WO/2007/065292A1 |
A type of optically pure diamides, which have the general formula as follows. The configuration is L or D, wherein Het represents 4-8 membered heterocycles contaning nitrogen atom on the backbone; each of R1, R2, R3 is hydrogen, hydrocar...
|
|
WO/2007/060828A1 |
Disclosed is a commercially advantageous method for obtaining a monomer by performing a depolymerization reaction of a polyamide. Specifically disclosed is a method for obtaining a monomer through a depolymerization reaction of a polyami...
|
|
WO2007037518A9 |
The invention is intended to provide a novel compound which is useful as an antibacterial agent and a manufacturing intermediate thereof and relates to a mutilin derivative represented by the formula (I) which is useful as an antibacteri...
|
|
WO/2007/057658A1 |
The present invention relates to a process for preparing arylated or vinylated olefins.
|
|
WO/2007/050425A2 |
A compound of formula I,wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein, useful as liver X receptor modulator.
|
|
WO/2007/048595A1 |
The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals.
|
|
WO/2007/045184A1 |
The invention provides peptides derivatives which 2-site contains proline or crico-amino acid having endothelium essence receptor antagonizing activity, its preparing process, medicinal compositions containing them, and their use in trea...
|
|
WO/2007/042656A1 |
The invention relates to the δ crystalline form of ivabradine hydrochloride having general formula (I), which is characterised by its X-ray diffraction pattern on powder. The invention is suitable for medicaments.
|
|
WO/2007/042657A1 |
The invention relates to the δd crystalline form of ivabradine hydrochloride having general formula (I), which is characterised by its X-ray diffraction pattern on powder. The invention is suitable for medicaments.
|
|
WO/2007/039138A1 |
The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neur...
|
|
WO/2007/035143A1 |
A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula (I): Also provided are uses of the composition as a medicament, and other uses and...
|
|
WO/2007/031429A1 |
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters th...
|
|
WO/2007/026224A2 |
The present invention relates to pharmaceutical compositions comprising benzyl(idene)-lactam derivatives of formula (I) wherein R1 is a group of the formula (G1) or (G2) depicted below, and a pharmaceutically acceptable salt or optical i...
|
|
WO/2007/028131A1 |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, d...
|
|
WO/2007/027719A2 |
The present invention provides analogs of formula (I) of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and ora...
|
|
WO/2007/028083A2 |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, ...
|
|
WO/2007/025709A2 |
The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments ...
|
|
WO/2007/028132A2 |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H- benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, de...
|
|
WO/2007/026654A1 |
Novel processes for easily producing an enamide and a dienamide from starting materials more inexpensive than conventional ones without generating any by-product. An N-vinylamide is reacted with an alkene in the presence of a ruthenium c...
|
|
WO/2007/028082A1 |
The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, ...
|
|
WO/2007/026971A2 |
This invention provides a process for preparing benzazepine compounds of the formula (1): wherein X1is a halogen atom, R1and R2are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield and hig...
|
|
WO/2007/024612A2 |
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft reject...
|
|
WO2005117882A9 |
The present invention provides compounds of Formula (I ) or (II), salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds...
|
|
WO/2007/020190A1 |
The invention relates to compounds of general formula (I), wherein R1 is lower alkyl substituted by halogen, or is aryl or heteroaryl, unsubstituted or substituted by halogen; R2is heterocycloalkyl, aryl or heteroaryl, which are unsubsti...
|
|
WO/2007/015263A2 |
An improved process for the crystallization of benazepril hydrochloride to obtain in at least 99.8% diastereomeric purity. The process comprises making a concentrated solution of benazepril hydrochloride in ethanol and adding the resulti...
|
|
WO/2007/012793A1 |
A process for preparing (S)-(+)- 10,11 -dihydro-10-hydroxy-5H- dibenz/b,f/azepine-5-carboxamide or (R)-(-)-10,l l-dihydro-10-hydroxy-5H- dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a ...
|
|
WO/2007/013697A1 |
Disclosed is a chiral phase-transfer catalyst having a simplified structure, which can be produced by reacting a 2,2'-dimethylenebromide-1,1'-binaphthyl derivative (which can be produced in relatively small numbers of steps) with a secon...
|
|
WO/2007/003934A2 |
There is provided a compound having Formula (I). In particular the present invention provides compounds capable of inhibiting 17β-hydroxysteroid dehydrogenase Type 3 (17β-HSD3).
|
